Bifogade filer
PDF
Kurs
-1,19%
Likviditet
0,41 MSEK
Kalender
| Est. tid* | ||
| 2026-02-05 | 08:30 | Bokslutskommuniké 2025 |
| 2025-11-13 | 08:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-21 | 08:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-30 | N/A | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2025-05-28 | N/A | Årsstämma |
| 2025-05-15 | 08:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-06 | - | Bokslutskommuniké 2024 |
| 2024-11-14 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-30 | - | Split EXPRS2 40:1 |
| 2024-08-15 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-07 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2024-06-05 | - | Årsstämma |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2023-11-16 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-17 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2023-05-24 | - | Årsstämma |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-23 | - | Extra Bolagsstämma 2023 |
| 2023-02-09 | - | Bokslutskommuniké 2022 |
| 2022-11-17 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-31 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2022-05-25 | - | Årsstämma |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2021-05-26 | - | Årsstämma |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-23 | - | Extra Bolagsstämma 2020 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-27 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2020-05-26 | - | Årsstämma |
| 2020-05-20 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2019-05-23 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2018-05-24 | - | Årsstämma |
| 2018-05-17 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-07 | - | Bokslutskommuniké 2017 |
| 2017-11-30 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-06-01 | - | X-dag ordinarie utdelning EXPRS2 0.00 SEK |
| 2017-05-31 | - | Årsstämma |
| 2017-05-24 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-19 | - | Extra Bolagsstämma 2017 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-08 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-31 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, 22 January 2024 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") will participate in investor and R&D events in the coming weeks. This Wednesday, January 24[th], CEO Bent Frandsen will present at the Redeye thematic event, Fight Cancer. Furthermore, Senior VP of R&D and Technology Dr. Max Søgaard will present at the Bio Innovation Leaders Summit taking place on February 7[th] and 8[th].
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company's website (https://expres2ionbio.com/events-list/).
24 January 2024 | Redeye thematic event: Fight Cancer
12:45 CET | Stockholm, Sweden
Join us at Redeye's thematic event, Fight Cancer, in Stockholm, on January 24[th] at 12:45 CET. CEO Bent Frandsen will present ExpreS2ion's therapeutic breast cancer vaccine program ES2B-C001 (HER2-cVLP). Learn more and register as a Redeye member to attend via Redeye's website (https://www.redeye.se/events/966280/redeye-theme-fight-cancer-2).
7-8 February 2024 | Bio Innovation Leaders Summit
Barcelona, Spain
ExpreS2ion Senior Vice President of R&D and Technology Dr. Max Søgaard is invited to present at the 16[th] Annual Bio Innovation Leaders Summit, to be held at the Hyatt Regency Barcelona Tower in Barcelona, Spain from 7 to 8 February 2024. For more information and to attend the event, please visit the Bio Innovation Leaders Summit website (https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.biosummit.co.uk%2F&data=05%7C01%7Cka%40expres2ionbio.com%7Cc69ecebfa5a746eab39508dbe1fb58c2%7Cd9c51f268469448688a5177c0976b407%7C0%7C0%7C638352241865480444%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=YPhBimJd93hDF5qmQx8Ir7MX3MeGbTvHou5EpTTcT%2Bw%3D&reserved=0). To set up a meeting with Dr. Søgaard, please send a meeting request to info@expres2ionbio.com.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com (ka@expres2ionbio.com)